Blueprint Medicines

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

BPMC reports strong Q1 earnings, eyes ASCO data and ISM launch

BPMC's Q1 earnings call highlighted strong financial performance, commercial progress with AYVAKYT, and promising developments in R&D. The company faces challenges in managing patient shifts and raising awareness for SM treatment but sees opportunities in upcoming data inflection points and the ISM launch. Overall, BPMC remains focused on driving growth and innovation in the biopharmaceutical space.

Blueprint Medicines reports strong Q2 performance and promising pipeline updates

Blueprint Medicines' Q2 2023 earnings call highlighted the successful launch of AYVAKIT, strong revenue performance, and promising updates on pipeline programs, while also addressing challenges in dose determination and recruitment acceleration.

Blueprint Medicines (BPMC) reports robust Q3 performance and eyes $1B market opportunity

BPMC's Q3 performance reflects strong revenue growth driven by AYVAKIT, with a focus on extending leadership in mast cell disorders. The company anticipates significant decreases in cash burn and operating expenses in 2024, with plans to provide more insight on their capital allocation strategy.

Blueprint Medicines reports strong 2023 performance and eyes international expansion

Blueprint Medicines had a strong financial performance in 2023, driven by AYVAKIT's success. The company is strategically positioned to capitalize on the growth potential of its key products. Challenges include maintaining growth momentum and successful international expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).

Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer

Shares of Blueprint Medicines Corp. gained 0.9% in premarket trading on Friday after the Food and Drug Administration on Thursday approved Ayvakit, the company's precision therapy treating a mutation in patients with gastrointestinal stromal tumors.

Blueprint prices new cancer drug at $32,000 per month

Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.

Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.

Blueprint Medicines Initiates Dosing in Liver Cancer Study

Blueprint Medicines' (BPMC) NDA for avapritinib to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) and fourth-line GIST is under FDA review. Other pipeline candidates also advance.

Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why

argenx

bluebird bio

Epizyme

Fate Therapeutics

Magenta Therapeutics Inc

The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.

Wedbush’s Top Picks After ASH Annual Meeting

Arrowhead Pharmaceuticals

Deciphera Pharmaceuticals

They have what deep-pocketed pharmaceutical giants want.

3 Stocks - That Could Be the Next Biotech Buyouts.

Blueprint Medicines (BPMC) posts favorable initial data from the part 1 of phase II PIONEER study on avapritinib for the treatment of patients with indolent systemic mastocytosis. Stock rises.

Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

Why Is Blueprint Medicines (BPMC) Up 1.4% Since Last Earnings Report?

Amarin Corporation Plc

Here's why you might want to buy Amarin and Blueprint Medicines as soon as possible.

2  Top Biotech Stocks to Buy Right Now

Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Blueprint Medicines (BPMC) Upgraded to Buy: What Does It Mean for the Stock?

Blueprint Medicines: GIST Setback Unlikely To Deter Future

Blueprint Medicines' (BPMC) loss is narrower than estimated in the third quarter with revenues also beating the mark. Shares rise.

Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates

Blueprint Medicines A Buy: Genome Biotech Development

The NDA for Blueprint Medicines' (BPMC) lead candidate avapritinib is currently under review in the United States. Heavy reliance on partners for collaboration revenues remains a concern.

Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance

Amgen

Eli Lilly

Mirati Therapeutics

Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.

4 Biotech Stocks With Big Catalysts in September

Why Is Blueprint Medicines (BPMC) Down 18.3% Since Last Earnings Report?

CEO and President of Blueprint Medicines Corp (30-Year Financial, Insider Trades) Jeffrey W.

Blueprint Medicines Corp (BPMC) CEO and President Jeffrey W. Albers Sold $1.6 million of Shares

Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.

Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark

Blueprint Medicines Corp (BPMC) CEO Jeffrey Albers on Q2 2019 Results - Earnings Call Transcript

Blueprint's 667 ORR jumps from 50% to 60% in 2L NSCLC. 60% ORR appears competitive and in line with Loxo's drug.

Blueprint Medicines Appears Increasingly Competitive In RET-Mutated NSCLC

Blueprint Medicines (BPMC) is a targeted-oncology play aiming to extend the lives of patients with gastrointestinal stromal tumors (GIST) and other genetically-relevant cancers.

Blueprint Medicines: Conviction In Precision Oncology

Axsome Therapeutics

Galapagos

Despite already massive gains this year, shares of these drugmakers could keep on climbing.

3 Soaring Biotech Stocks With More Fuel in the Tank

It looks like this biotech has what big-pharma companies have been eager to acquire.

Here's Why Blueprint Medicines Stock Rose 75% in the First Half of 2019

Here's why these very different drugmakers could both receive a big buyout offer before the end of 2019.

News for Blueprint Medicines Stock (BPMC)